Monaco Federica, Purpari Giuseppa, Di Gennaro Annapia, Mira Francesco, Di Marco Patrizia, Guercio Annalisa, Savini Giovanni
Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale". Campo boario, 64100, Teramo.
Vet Ital. 2019 Mar 31;55(1):73-79.
To evaluate the immunological response following vaccination, 40 WNV serologically negative horses were selected and divided in two groups of 20 animals. One group was vaccinated (booster after 28 days) with a whole inactivated viral strain and the second group with a live recombinant canarypox virus expressing the genes coding for the WNV preM/E viral proteins. IgM, IgG and neutralizing antibodies were monitored by class specific ELISAs and serum neutralization assay for 360 days. In both groups, IgM antibodies were first detected 7 days post vaccination (dpv). However, in the group vaccinated with inactivated vaccine, IgM antibodies were detected until day 42 pv, whereas in the group vaccinated with the recombinant vaccine, they were detected up to day 52 pv. A similar (P > 0.05) proportion of horses showed IgM antibodies after vaccination with either recombinant [30%; 95% confidence interval (CI): 14.59%-52.18%] or inactivated (32%; 95% CI: 15.39-54.28%) vaccine. Both vaccines induced in vaccinated horses a detectable IgG antibody response starting from day 7 pv and lasting till the end of the trial. Analogously, both products elicited WNV specific neutralizing antibodies. The response induced by the live canarypox virus-vectored vaccine was higher (mean titres 1:298 vs 1:18.9) and lasted longer than did that induced by the killed-virus vaccines. In fact, one year after the vaccination, neutralizing antibodies were still detectable in the horses which received the canarypox virus-based vaccine but not in the group vaccinated with the killed product. The use of vaccines is a valuable tool to prevent WNV disease in horses and the availability of different products facilitates the control of the disease in endemic areas.
为评估接种疫苗后的免疫反应,选取40匹西尼罗河病毒血清学阴性的马匹并将其分为两组,每组20只动物。一组用全灭活病毒株进行接种(28天后加强免疫),另一组用表达编码西尼罗河病毒前膜/包膜(preM/E)病毒蛋白基因的重组金丝雀痘病毒进行接种。通过类特异性酶联免疫吸附测定(ELISA)和血清中和试验对IgM、IgG和中和抗体进行了360天的监测。在两组中,接种疫苗后7天(dpv)首次检测到IgM抗体。然而,在接种灭活疫苗的组中,直到接种后42天仍能检测到IgM抗体,而在接种重组疫苗的组中,直到接种后52天仍能检测到。接种重组疫苗[30%;95%置信区间(CI):14.59%-52.18%]或灭活疫苗(32%;95%CI:15.39-54.28%)后,显示出IgM抗体的马匹比例相似(P>0.05)。两种疫苗均在接种马匹中诱导出可检测到的IgG抗体反应,从接种后7天开始,一直持续到试验结束。类似地,两种产品均引发了西尼罗河病毒特异性中和抗体。重组金丝雀痘病毒载体疫苗诱导的反应更高(平均滴度1:298对1:18.9),且持续时间比灭活病毒疫苗诱导的反应更长。事实上,接种疫苗一年后,接受基于金丝雀痘病毒疫苗的马匹中仍可检测到中和抗体,而接种灭活产品的组中则未检测到。疫苗的使用是预防马匹西尼罗河病毒病的一项重要工具,不同产品的可获得性有助于在流行地区控制该疾病。